Juan F. Santibanez

Dr. Juan F. Santibanez

Group of Molecular Oncology, Institute for Medical Research, University of Belgrade, Belgrade, Serbia
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
Jelena KrsticJelena Krstic
Jelena Krstic
Drenka TrivanovićDrenka Trivanović
Drenka Trivanović
SMSlavko Mojsilović
Slavko Mojsilović
Juan F. SantibanezJuan F. Santibanez
Juan F. Santibanez
Transforming growth factor-beta (TGF-β) and oxidative stress/Reactive Oxygen Species (ROS) both have pivotal roles in health and disease. In this review we are analyzing the interplay between TGF-βand ROS in tumorigenesis and cancer progression. They have contradictory roles in cancer progression since both can have antitumor effects, through the induction of cell death, senescence and cell cycle arrest, and protumor effects by contributing to cancer cell spreading, proliferation, survival, and metastasis. TGF-βcan control ROS production directly or by downregulating antioxidative systems. Meanwhile, ROS can influence TGF-βsignaling and increase its expression as well as its activation from the latent complex. This way, both are building a strong interplay which can be taken as an advantage by cancer cells in order to increment their malignancy. In addition, both TGF-βand ROS are able to induce cell senescence, which in one way protects damaged cells from neoplastic transformation but also may collaborate in cancer progression. The mutual collaboration of TGF-βand ROS in tumorigenesis is highly complex, and, due to their differential roles in tumor progression, careful consideration should be taken when thinking of combinatorial targeting in cancer therapies.

8 September 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
LCLuca Cassetta
Luca Cassetta
KBKirsten Bruderek
Kirsten Bruderek
JSJoanna Skrzeczynska-Moncznik
Joanna Skrzeczynska-Moncznik
OOOktawia Osiecka
Oktawia Osiecka
XHXiaoying Hu
Xiaoying Hu
Sven BrandauSven Brandau
Sven Brandau
Background Myeloid-derived suppressor cells (MDSC) are a functional myeloid cell subset that includes myeloid cells with immune suppressive properties. The presence of MDSC has been reported in the peripheral blood of patients with several malignant and non-malignant diseases. So far, direct comparison of MDSC across different diseases and Centers is hindered by technical pitfalls and a lack of standardized methodology. To overcome this issue, we formed a network through the COST Action Mye-EUNITER (www.mye-euniter.eu) with the goal to standardize and facilitate the comparative analysis of human circulating MDSC in cancer, inflammation and infection. In this manuscript, we present the results of the multicenter study Mye-EUNITER MDSC Monitoring Initiative, that involved 13 laboratories and compared circulating MDSC subsets across multiple diseases, using a common protocol for the isolation, identification and characterization of these cells. Methods We developed, tested, executed and optimized a standard operating procedure for the isolation and immunophenotyping of MDSC using blood from healthy donors. We applied this procedure to the blood of almost 400 patients and controls with different solid tumors and non-malignant diseases. The latter included viral infections such as HIV and hepatitis B virus, but also psoriasis and cardiovascular disorders. Results We observed that the frequency of MDSC in healthy donors varied substantially between centers and was influenced by technical aspects such as the anticoagulant and separation method used. Expansion of polymorphonuclear (PMN)-MDSC exceeded the expansion of monocytic MDSC (M-MDSC) in five out of six solid tumors. PMN-MDSC expansion was more pronounced in cancer compared with infection and inflammation. Programmed death-ligand 1 was primarily expressed in M-MDSC and e-MDSC and was not upregulated as a consequence of disease. LOX-1 expression was confined to PMN-MDSC. Conclusions This study provides improved technical protocols and workflows for the multi-center analysis of circulating human MDSC subsets. Application of these workflows revealed a predominant expansion of PMN-MDSC in solid tumors that exceeds expansion in chronic infection and inflammation.

1 January 2014 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
Jelena KrsticJelena Krstic
Jelena Krstic
Juan F. SantibanezJuan F. Santibanez
Juan F. Santibanez
Transforming growth factor-beta (TGF-β) is a pleiotropic factor with several different roles in health and disease. In tumorigenesis, it may act as a protumorigenic factor and have a profound impact on the regulation of the immune system response. Matrix metalloproteinases (MMPs) are a family that comprises more than 25 members, which have recently been proposed as important regulators acting in tumor stroma by regulating the response of noncellular and cellular microenvironment. Tumor stroma consists of several types of resident cells and infiltrating cells derived from bone marrow, which together play crucial roles in the promotion of tumor growth and metastasis. In cancer cells, TGF-βregulates MMPs expression, while MMPs, produced by either cancer cells or residents’ stroma cells, activate latent TGF-βin the extracellular matrix, together facilitating the enhancement of tumor progression. In this review we will focus on the compartment of myeloid stroma cells, such as tumor-associated macrophages, neutrophils, and dendritic and mast cells, which are potently regulated by TGF-βand produce large amounts of MMPs. Their interplay and mutual implications in the generation of pro-tumorigenic cancer microenvironment will be analyzed.


21 May 2018 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
ABAnnika M. Bruger
Annika M. Bruger
ADAnca Dorhoi
Anca Dorhoi
GEGunes Esendagli
Gunes Esendagli
KBKatarzyna Barczyk-Kahlert
Katarzyna Barczyk-Kahlert
PBPierre van der Bruggen
Pierre van der Bruggen
Sven BrandauSven Brandau
Sven Brandau

Verified
Journal Article
Open access
PDF file
CECesar Echeverria
Cesar Echeverria
Juan F. SantibanezJuan F. Santibanez
Juan F. Santibanez
ODOscar Donoso-Tauda
Oscar Donoso-Tauda
CECarlos A. Escobar
Carlos A. Escobar
RRRodrigo Ramirez-Tagle
Rodrigo Ramirez-Tagle
Relationships between the structural characteristic of synthetic chalcones and their antitumoral activity were studied. Treatment of HepG2 cells for 24 h with synthetic 2’-hydroxychalcones resulted in apoptosis induction and dose-dependent inhibition of cell proliferation. The calculated reactivity indexes and the adiabatic electron affinities using the DFT method including solvent effects, suggest a structure-activity relationship between the Chalcones structure and the apoptosis in HepG2 cells. The absence of methoxy substituents in the B ring of synthetic 2’-hydroxychalcones, showed the mayor structure-activity pattern along the series.